Current first-line standard of care for patients with unresectable CRC is chemotherapy in combination with monoclonal antibodies (mAbs), including anti–epidermal growth factor receptor (EGFR) mAbs or the anti–vascular endothelial growth factor (VEGF) mAb. The gene discussed is VEGFA; the disease is colorectal carcinoma.